General Experimental
Unless noted, all operations were performed without taking precautions to exclude air and moisture. All solvents and reagents were purchased from commercial sources and were used without further purification.
The sulfo-cyanine3-maleimide (Cy3-MI) and cyanine5-N-Hydroxysuccinimide-ester (Cy5-NHS) were purchased from Lumiprobe. 7-Diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin (CPM) and Alexa fluor 647 C2 maleimide (Alexa647-MI) were purchased from Thermo Fisher Life Technologies. Atto550-maleimide (Atto550-MI) was purchased from ATTO-TEC GmbH. The peptide (CATSICGGGC, 95% purity) was purchased from GL Biochem China. Recombinant
Human Interleukin-2 was received from Cell Science, MA. MALDI-TOF-MS spectra were acquired on a Bruker Reflex III.
HR-MALDI-MS was recorded on a Solarix (Bruker) FTICR-MS. The absorbance and emission measurements were recorded using TECAN M1000 microplate reader.
Sequential modification of Interleukin-2 2.1 Structure of sulfo-cyanine3-maleimide and allyl-sulfone-cyanine5
Figure S1. Chemical structure of (A) sulfo-cyanine3-maleimide (Cy3-MI) and (B) allyl-sulfone-cyanine5
(Allyl-sulfone-Cy5 14) The Allyl-sulfone-Cy5 14 was synthesized following the synthetic procedure reported earlier.
Synthesis and characterization of 3,3-dimethyl-1-(6-oxo-6-((2-(2-((2-(tosylmethyl)acryloyl)oxy)ethoxy)ethyl)amino)hexyl)-2-((1E,3E)-5-((Z
1
Synthesis of tert-butyl (2-(2-hydroxyethoxy)ethyl)carbamate 10.
In a 250 mL round bottom flask, 2-(2-aminoethoxy)ethanol (3.15 g, 30 mmol) was dissolved in 80 mL of dichloromethane (DCM) and Triethylamine (TEA, 5 mL, 36 mmol, 1.2 equiv.) was added. Thereafter, di-tert-butyl dicarbonate (Boc, 7.85 g, 36 mmol, 1.2 equiv.) dissolved in 10 mL of DCM and dropped slowly to the solution. The reaction mixture was stirred overnight at room temperature and the solvent was removed under vacuum. 
Synthesis of 2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethyl methacrylate 11.
In a 250 mL Schlenk flask, tert-butyl (2-(2-hydroxyethoxy)ethyl)carbamate 10 (1.85 g, 9 mmol) and TEA (2.22 mL,16 mmol, 1.8 equiv.) were dissolved in 60 mL of dry DCM and cooled to 0 °C. Then methacryloyl chloride (1.62 mL, 16 mmol, The absorbance of IL2-Cy3 2 at 554 nm is 0.0102, which was fitted in the calibration curve ( Figure S4A ) and 10.76 µg/mL (14.62 µM) of Cy3-MI was calculated to be attached on the IL-2. In addition, the concentration of IL-2 is 300 µg/mL (19.5 µM) from the gel densitometry. Therefore, the labeling efficiency of Cy3-MI is 75% (=14.62/19.5*100%). Similarly, the absorbance of Cy5 in IL2-Cy3-Cy5 3 at 650 nm is 0.0194, which was fitted in the calibration curve ( Figure S4B ) and 0.00163 mg/mL (1.43 µM) of Allyl-sulfone-Cy5 was calculated to be attached on the IL2-Cy3 2. From the gel densitometry, the concentration of IL-2 in IL2-Cy3-Cy5 3 is 40 µg/mL (2.6 µM). Therefore, the labeling efficiency of Allyl-sulfone-Cy5 is 55% (=1.43/2.6*100%). 
Bio-activity study of IL-2 1, IL2-Cy3 2 and IL2-Cy3-Cy5 3
To determine the biological activity of the modified IL-2, the IL-2-dependent murine cell line: CTLL-2 was used.
Proliferation experiments were performed in RPMI1640 medium, supplemented with 10% FCS, 2 mM L-glutamine and 50 3 were titrated and compared to native IL-2 1 in the following concentrations 200, 100, 10, 1, 0.5, 0.25, 0.1, 0.01 U/mL. For culture maintenance the CTLL-2 cells were incubated in CTLL-2 medium supplemented with 50 U/mL of IL-2.
2.5.1
Bio-activity study of disulfide reduced Interleukin-2.
To study the effect of disulfide bond of IL-2 in its bio-activity we synthesized a derivatives in which, the disulfide bond of IL-2 was reduced and labelled by N-(2-aminoethyl)maleimide. The IL-2 1 (100 µg, 6.2 nmol) was first reacted with 10 equivalents of (tris(2-carboxyethyl)phosphine) (62 nmol) in 50 mM Phosphate buffer at pH 7.4 at 15 ᵒC, stirring for 30 minutes under argon atmosphere. Then, the reaction mixture was divided into two portions and one portion containing was used for subsequent reaction. To 50 ug of reduced IL-2 (3.2 nmol) was added excess N-(2-aminoethyl)maleimide (20 equiv., 62 nmol) and the reaction was stirred at 15 ᵒC for 24 h. Thereafter, the protein was purified by size exclusion chromatography using Zeba Spin desalting columns (MWCO 7000) to yield 2'. IL-2 received from Cell Science was used as a control for evaluation of the biological activity. Prior to evaluation of the bioactivity, the concentration of IL-2 in each of the three samples was normalized by absorbance measurement at 280 nm. The bio-activity was measured by CTLL-2 cells assay as described above. 
Synthesis of tri-CPM labelled model peptide 6
The mono-labeled model peptide 5 (0.5 mg, 0.39 µmol) was dissolved in 1 mL of 100 mM Phosphate buffer. TCEP (0.2 mg, 0.7 µmol) was added and the solution was incubated for 30 min. CPM (0.6 mg, 1.49 µmol) was dissolved in 1 mL ACN and added slowly to the above mixture. The reaction solution was stirred for 3 h at RT. The product was purified by preparative HPLC using an Atlantis Prep OBD T3 column (19 x 100 mm, 5 µm) with the mobile phase starting from 100% solvent A 
Sequential modification of Dis-tag-EYFP

Expression of EYFP
Plasmid preparation
The method add-on-PCR was employed to attach the tag sequence at the N-terminus of a model protein EYFP. Plasmid 
Protein purification
The pET22b(+)-Y3 plasmid was transferred into E.coli BL21 (DE3) bacteria via electroporation. 200 mL LB medium (Alfa Aesar, 20 g/L) supplemented with 100 µg/mL ampicillin (Sigma-Aldrich) was inoculated and the expression culture grown at 37 °C 170 rpm until OD 578 reached ~0.6. Protein production was initiated by the addition of 0.01 mM IPTG (AppliChem, The bacterial cells were disrupted via ultra-sonication. The lysate was centrifuged to separate the soluble portion which was filtered through a 0.2 µm syringe filter prior loading onto a Ni 2+ charged and 2x PBS equilibrated 1 mLHiTrap™ FF IMAC column from GE Healthcare. The column was washed with ten column volumes (cv) of 2x PBS, 10 mM imidazole and the protein eluted with three cv of 2x PBS, 500 mM imidazole. The protein was transferred into fresh 2x PBS pH 7.4 using a Vivaspin 6 (Sartorius Group, MWCO 10k) centrifugal concentrator.
Structure of Alexa647-Maleimide
Figure S8 Chemical Structure of Alexa 647 C2 Maleimide (Alexa647-MI). Chemical Structure of Atto550-maleimide (Atto550-MI) is not available.
Sequential dual-labelling of Dis-tag-EYFP
The Dis-tag-EYFP 7 (1 mg, 0.034 µmol) and 5 equivalents of Atto550-MI (0.14 mg, 0.172 µmol) were stirred in PBS buffer (2x, pH 7.4) for 3 h under argon atmosphere. The reaction mixture was purified by size exclusion chromatography using a Atto-EYFP 8, lane 4: Atto-Alexa-EYFP 9a.
Determination of labelling efficiency
The absorbance of Atto-EYFP 8a at 554 nm is 0.3187, which was fitted in the calibration curve ( Figure S10A ) and 0.005724 mg/mL (7.02 µM) of Atto550-MI was calculated to be attached on the EYFP. In addition, the concentration of Atto-EYFP 8a is 0.338 mg/mL (11.66 µM) from the gel densitometry. Therefore, the labeling efficiency of Atto550-MI is 60% (=7.015/11.66*100%). Similarly, the absorbance of Atto-Alexa-EYFP 9a at 652 nm is 0.104, which was fitted in the calibration curve ( Figure S10B ) and 0.00163 mg/mL (1.25 µM) of Alexa647-MI was calculated to be attached on the EYFP.
From the gel densitometry, the concentration of Atto-Alexa-EYFP 9a is 0.0875 mg/mL (3.02 µM). Therefore, the labeling efficiency of Alexa647 is 42% (=1.254/3.017*100%).
Figure S10
The calibration curve of the concentration of (A) Atto-550 and (B) Alexa-647 based on the absorbance at 554 nm and 652 nm respectively measured in phosphate buffer at pH 7.4.
Dual color labeling on Dis-tag-EYFP for single-molecule FRET.
Figure S11 In order to measure the single-molecule FRET, the Dis-tag-EYFP was labeled with Alexa647-MI and Atto550-MI sequentially ( Figure S11 ). The Alexa647 was labeled first instead of Atto550, since the Dis-tag-EYFP (0.2 mg, 6.9 nmol) was reacted with 3 eq. of Alexa647-MI (0.027 mg, 20.7 nmol) in 50 mM phosphate buffer (pH 7.4) for 3 h under argon atmosphere. The reaction mixture was purified by size exclusion chromatography using Sephadex G-25 matrix. Thereafter, Alexa-EYFP 8b (0.1 mg, 3.4 nmol) was sequentially reacted with TCEP (9.9 μg, 34.5 nmol) for 1 h and Atto550-MI (8.4 μg, 10.3 nmol) for 3 h. The resulting Alexa-Atto-EYFP 9b was purified by size exclusion chromatography using Sephadex G-25 matrix. The labeling efficiency for Alexa647-MI and Atto550-MI were 47% and 94 % respectively based on the absorbance spectra ( Figure S11 ). The detailed calculation was shown in the following part.
4.3.2
Calculation of the labeling efficiency.
Alexa647-MI labeling efficiency.
A . Therefore, the labeling efficiency of Alexa647-MI is 1.04x10 -6 /2.205x10 -6 = 47%.
Specification:
A 514 (8a) and A 652 (8a) are the absorbance of Alexa-EYFP 7 at 514 nm and 652 nm respectively.
A 514 (Alexa) = 0.8% A max (Alexa), means the absorbance of Alexa647-MI at 514 nm is 0.8% of its maximum absorbance according to its absorbance spectrum.
ε EYFP and ε Alexa are the extinction coefficient of EYFP and Alexa647-MI respectively.
Atto550-MI labeling efficiency.
A . Therefore, the labeling efficiency of Atto550-MI is 2.556x10 -6 /2.703x10 -6 = 94%.
Specification:
A 516 (8b), A 562 (8b) and A 652 (9b) are the absorbance of Alexa-Atto-EYF P 8 at 516 nm, 562 nm and 656 nm respectively.
A 562 (Alexa) = 6.57%A max (Alexa), means the absorbance of Alexa647-MI at 562 nm is 6.57% of its maximum absorbance according to its absorbance spectrum.
A 516 (Alexa) = 0.8% A max (Alexa), means the absorbance of Alexa647-MI at 516 nm is 0.8% of its maximum absorbance according to its absorbance spectrum.
A 516 (Atto) = 28.5%A max (Atto), means the absorbance of Atto550-MI at 516 nm is 28.5% of its maximum absorbance according to its absorbance spectrum.
ε EYFP and ε Atto are the extinction coefficient of EYFP and Atto550-MI respectively. 
Experimental Setup and Data Analysis
Single-molecule (sm)FRET experiments were performed on a homebuilt prism-based total internal reflection fluorescence microscope (TIRFM) as described previously. 2 Briefly, fluorescence was collected through a water-immersion objective and split into a donor and acceptor emission channel using a dichroic mirror. The fluorescence signal of the donor and acceptor emission was each directed to an EMCCD camera (iXon DU-897E-CS0-BV, Andor), images of both cameras where overlaid using fluorescent beads which could be detected simultaneously in both channels for calibration. The donor and acceptor molecules were excited using the alternating laser excitation scheme (ALEX) 3 with an excitation wavelength of 532nm. For direct excitation of the acceptor molecules a diode laser (643 nm, Toptica) was used.
Microfluidic chambers were constructed similar to a procedure published previously. 4 Fluorescent samples were deposited onto a PEG/Biotin-coated chamber surface. All measurements were recorded with an integration time of 100 ms per frame and a total duration of 60 s.
The acquired data was analyzed using custom-written MATLAB (The MathWorks) software as described elsewhere. 5 For the calculation of the FRET efficiency of each individual FRET pair, the following formula was used: I A and I D are the background corrected intensities from acceptor and donor channels and I and I' are the intensities before and after acceptor photobleaching, respectively. The correction factor β accounts for the leakage of the donor emission into the acceptor channel whereas the γ factor corrects for different quantum yields of donor and acceptor dyes and different detection efficiencies of the two channels. Including a corection factor for the direct excitation of the acceptor by the 532nm did not change the result and was therefore omitted for simplicity. All parameters for the calculation of the FRET value were estimated as described previously. 6 Since the observed smFRET efficiencies were larger than 90%, the histograms were fitted with a Beta distribution. 7 The mean FRET efficiency as well as its standard error were determined from the fit.
Molecules with values below 0.25 and above 1.5 were excluded from the analysis. 
